$0.51
1.22% today
Nasdaq, Feb 28, 05:18 pm CET
ISIN
US92536C1036
Symbol
VERU

Veru Inc Stock price

$0.52
-0.12 18.71% 1M
-0.32 38.54% 6M
-0.13 20.63% YTD
-0.13 20.10% 1Y
-5.07 90.76% 3Y
-3.74 87.88% 5Y
-2.95 85.12% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.01 2.68%
ISIN
US92536C1036
Symbol
VERU

Key metrics

Market capitalization $75.58m
Enterprise Value $52.49m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.56
P/S ratio (TTM) P/S ratio 5.12
P/B ratio (TTM) P/B ratio 2.84
Revenue growth (TTM) Revenue growth -7.43%
Revenue (TTM) Revenue $14.75m
EBIT (operating result TTM) EBIT $-40.28m
Free Cash Flow (TTM) Free Cash Flow $-27.15m
Cash position $26.61m
EPS (TTM) EPS $-0.23
P/E forward negative
P/S forward 22.36
EV/Sales forward 15.53
Short interest 11.47%
Show more

Is Veru Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Veru Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Veru Inc forecast:

4x Buy
80%
1x Hold
20%

Analyst Opinions

5 Analysts have issued a Veru Inc forecast:

Buy
80%
Hold
20%

Financial data from Veru Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
15 15
7% 7%
100%
- Direct Costs 10 10
27% 27%
69%
4.64 4.64
42% 42%
31%
- Selling and Administrative Expenses 28 28
34% 34%
188%
- Research and Development Expense 17 17
51% 51%
114%
-40 -40
42% 42%
-271%
- Depreciation and Amortization 0.26 0.26
7% 7%
2%
EBIT (Operating Income) EBIT -40 -40
41% 41%
-273%
Net Profit -34 -34
47% 47%
-232%

In millions USD.

Don't miss a Thing! We will send you all news about Veru Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Veru Inc Stock News

Neutral
Seeking Alpha
15 days ago
Veru Inc (NASDAQ:VERU ) Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications. Mitchell Steiner - Chairman, Chief Executive Officer and President Michelle Greco - CFO and CAO Gary Barnette - Chief Scientific Officer Conference Call Participants William Wood - B.
Neutral
GlobeNewsWire
15 days ago
--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical function-- -- The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommen...
Neutral
GlobeNewsWire
about one month ago
-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% less lean mass than patients receiving WEGOVY alone --
More Veru Inc News

Company Profile

Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.

Head office United States
CEO Mitchell Steiner
Employees 210
Founded 1971
Website www.verupharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today